

Heat-Solubilized Curcumin Should Be Considered in Clinical Trials for Increasing Bioavailability

To the Editor: The recent article by Dhillon et al. (1) is of great interest to those working with curcumin. As the investigators suggest, the usefulness of curcumin could be minimized because of its poor oral bioavailability (2). Data from this study show that only 22 to 41 ng/mL were detectable in plasma even when 8 g curcumin/day was given orally (1). Curcumin levels in the microgram range have been shown to be necessary to show antiproliferative effects in *in vitro* studies (3).

The solution to this problem would be to increase the solubility of curcumin before oral administration to patients. We have shown that we could increase the solubility of curcumin 12-fold by heating a solution of curcumin in water to boiling for 10 minutes (4). Matrix-assisted laser desorption ionization mass spectrometric and spectrophotometric profiling (400-700 nm) of the heat-extracted curcumin displays no heat-mediated disintegration of curcumin. With the use of an ELISA that used 4-hydroxy-2-nonenal modification of solid-phase antigen, the heat-solubilized curcumin was found to inhibit 4-hydroxy-2-nonenal-protein modification by 80% (5). We showed that mild alkali-solubilized curcumin also inhibited 4-hydroxy-2-nonenal protein modification significantly (6). Thus, inhibition of 4-hydroxy-2-nonenal modification of proteins may be a mechanism by which curcumin exerts its effect in many disorders (4, 5).

As the full pharmacologic potential of curcumin is limited because of its extremely limited water solubility, heat-solubilized curcumin should be considered in clinical trials involving curcumin.

Biji T. Kurien
R. Hal Scofield
Arthritis and Immunology Program,
Oklahoma Medical Research Foundation,
Oklahoma City, Oklahoma

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

1. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. *Clin Cancer Res* 2008;14:4491–9.
2. Lao CD, Ruffin MT IV, Normolle D, et al. Dose escalation of a curcuminoid formulation. *BMC Complement Altern Med* 2006;6:10.
3. Li L, Aggarwal BB, Shishodia S, et al. Nuclear factor- κ B and I κ B kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. *Cancer* 2004;101:2351–62.
4. Kurien BT, Singh A, Matsumoto H, et al. Improving the solubility and pharmacological efficacy of curcumin by heat treatment. *Assay Drug Dev Technol* 2007;5:567–76.
5. Kurien BT, Scofield RH. *In vitro* modification of solid phase multiple antigenic peptides/autoantigens with 4-hydroxy-2-nonenal (HNE) provide ideal substrates for detection of anti-HNE antibodies and peptide antioxidants. *J Immunol Methods* 2005;303:66–75.
6. Kurien BT, Scofield RH. Curcumin/turmeric solubilized in sodium hydroxide inhibits HNE protein modification-an *in vitro* study. *J Ethnopharmacol* 2007;110:368–73.

© 2009 American Association for Cancer Research.
doi:10.1158/1078-0432.CCR-08-1957

Clinical Cancer Research

Heat-Solubilized Curcumin Should Be Considered in Clinical Trials for Increasing Bioavailability

Biji T. Kurien and R. Hal Scofield

Clin Cancer Res 2009;15:747.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/15/2/747.1>

Cited articles This article cites 6 articles, 1 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/15/2/747.1.full#ref-list-1>

Citing articles This article has been cited by 1 HighWire-hosted articles. Access the articles at:
<http://clincancerres.aacrjournals.org/content/15/2/747.1.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/15/2/747.1>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.